<DOC>
	<DOCNO>NCT00630019</DOCNO>
	<brief_summary>Compare ocular tissue level follow topical ocular instillation 1.5 % levofloxacin ophthalmic solution active comparator subject undergoing cataract surgery .</brief_summary>
	<brief_title>Ocular Tissue Levels 1.5 % Levofloxacin Ophthalmic Solution Compared Active Comparator</brief_title>
	<detailed_description />
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Capable instill eye drop Scheduled cataract surgery intraocular lens ( IOL ) implantation Be medically clear surgery Women must postmenopausal ( least 1 year ) , surgically sterile , abstinent , , sexually active , practice effective method birth control entry , must agree continue use method contraception throughout study Women childbearing potential must negative urine pregnancy test screening . Willing adhere prohibition restriction specify protocol . Subjects ( his/her legally acceptable representative ) must sign informed consent document indicate understand purpose procedure require study willing participate study . Known allergy contraindication test article ( ) component . Presence abnormality significant illness eye investigator 's opinion could affect subject 's health study parameter . History presence corneal pathology disease Presence active ocular infection ( bacterial , viral fungal ) , positive history ocular herpetic infection . History severe dry eye syndrome . History evidence previous ocular surgery operative eye . History significant illness could expect interfere study parameter . Use disallow therapy ( systemic topical ) : Fluoroquinolone antiinfective agent ( systemic topical ) within 2 week Visit 1 anytime Visit 1 duration study ; Topical ophthalmic preparation ( include tear substitute rewetting drop ) , within 1 week Visit 1 anytime Visit 1 duration study ( study medication restrict ) , exception nonsteroidal topical ophthalmic drop Use contact lenses 2 week prior study duration study . Received experimental drug use experimental medical device within 30 day plan start treatment . Pregnant breastfeeding . Any condition , opinion investigator , would compromise wellbeing subject study . Employees investigator study center , direct involvement propose study study direction investigator study center , well family member employee investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Aqueous humor penetration anti-infectives</keyword>
</DOC>